CG Oncology (CGON) Competitors

BridgeBio Pharma (NASDAQ:BBIO) and CG Oncology (NASDAQ:CGON) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, community ranking, analyst recommendations, earnings and valuation.

Do institutionals and insiders hold more shares of BBIO or CGON?

99.8% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 26.6% of CG Oncology shares are held by institutional investors. 18.2% of BridgeBio Pharma shares are held by insiders. Comparatively, 7.4% of CG Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Does the media favor BBIO or CGON?

In the previous week, CG Oncology had 1 more articles in the media than BridgeBio Pharma. MarketBeat recorded 17 mentions for CG Oncology and 16 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.80 beat CG Oncology's score of 0.66 indicating that BridgeBio Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	10 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CG Oncology	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has preferable earnings & valuation, BBIO or CGON?

CG Oncology has lower revenue, but higher earnings than BridgeBio Pharma. CG Oncology is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$127.42M	48.94	-$535.76M	-$3.53	-9.30
CG Oncology	$662K	3,019.06	-$48.61M	-$1.51	-17.36

Do analysts prefer BBIO or CGON?

BridgeBio Pharma currently has a consensus price target of $57.09, suggesting a potential upside of 73.85%. CG Oncology has a consensus price target of $58.22, suggesting a potential upside of 122.05%. Given CG Oncology's stronger consensus rating and higher probable upside, analysts clearly believe CG Oncology is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	0 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.92
CG Oncology	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	3.00

Is BBIO or CGON more profitable?

BridgeBio Pharma has a net margin of -241.44% compared to CG Oncology's net margin of -10,642.98%. BridgeBio Pharma's return on equity of 0.00% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-241.44%	N/A	-75.69%
CG Oncology	-10,642.98%	-18.97%	-15.36%

Which has more risk & volatility, BBIO or CGON?

BridgeBio Pharma has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500. Comparatively, CG Oncology has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500.

Does the MarketBeat Community prefer BBIO or CGON?

BridgeBio Pharma received 150 more outperform votes than CG Oncology when rated by MarketBeat users. However, 90.63% of users gave CG Oncology an outperform vote while only 72.47% of users gave BridgeBio Pharma an outperform vote.

Company	Underperform	Outperform
BridgeBio Pharma	Outperform Votes 179 72.47%	Underperform Votes 68 27.53%
CG Oncology	Outperform Votes 29 90.63%	Underperform Votes 3 9.38%

Summary

BridgeBio Pharma beats CG Oncology on 10 of the 19 factors compared between the two stocks.